Full-Time

Manager – Global Clinical Supply Chain Import-Export Operations

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$108.5k - $170.5k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Cambridge, MA, USA

Category
Supply Chain Management
Transportation & Distribution
Operations & Logistics
Requirements
  • Bachelor’s Degree, preferred in Business, Science or Law
  • 6 or more years’ experience in R&D material management/clinical supplies/logistics, including 4 years’ experience in importing and exporting in pharmaceutical, chemical, munitions, high end electronics or biopharma industry.
  • Strong understanding and experience with international trade compliance laws and regulations including but not limited to, imports, exports, economic sanctions, Harmonization Tariff system (HTS), country of origin, and Free Trade Agreements.
Responsibilities
  • Manage daily import and export transactions by providing direction and oversight to logistic vendors while simultaneously executing communication with cross functional Takeda teams to ensure the shipping process meets product quality control standards, project timelines and staying compliant with all Import and Export regulations including those of US Government, EU Government, CBP, USDA, FDA, Fish Wildlife, CDC, and any other potential foreign government agencies.
  • Prepare relevant import/export documents (i.e., customs invoices, application for import/export permits) and determine classifications such as Country of Origin, HTS Codes, Export Commerce Control Number (ECCN), FDA product codes, and customs valuations for products imported/exported in support Takeda projects.
  • Instruct customs brokers and freight forwarders on the clearance of import/export transactions.
  • Create educational and proactive communications to influence different functional groups to ensure import/export solutions being considered adhere to international trade regulations and product quality.
  • Assist in the management of the development of contracts, maintain vendor relationships and ensure the cost-effective performance of all international logistical services providers (forwarders/carriers).
  • Develop and maintain updated control documents (policies, procedures, processes, and work instructions) for Import and Export activities by collaborating with global import/export groups.
  • Work with internal stakeholders proactively to influence and ensure import/export solutions being considered adhere to international trade regulations and product quality.
  • Identify key opportunities for process improvements and implement solutions to eliminate compliance deficiencies in import/export operations.
  • Optimize cold chain and temperature-controlled shipments to ensure regulatory compliance and product integrity.
Desired Qualifications
  • HAZMAT Certification IATA and DOT
  • US Customs Broker License

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline aiming for multiple product launches in the coming years. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...